newsfilter
← Latest News
Business Wire·

Medincell: The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

The olanzapine long-acting injectable (TEV-'749 / mdc-TJK) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks. If approved, TEV-‘749 could help fill a